KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ionis Pharmaceuticals (IONS) Cost of Revenue: 2018-2024

Historic Cost of Revenue for Ionis Pharmaceuticals (IONS) over the last 7 years, with Dec 2024 value amounting to $11.2 million.

  • Ionis Pharmaceuticals' Cost of Revenue rose 118.30% to $2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.8 million, marking a year-over-year increase of 12.77%. This contributed to the annual value of $11.2 million for FY2024, which is 22.80% up from last year.
  • According to the latest figures from FY2024, Ionis Pharmaceuticals' Cost of Revenue is $11.2 million, which was up 22.80% from $9.1 million recorded in FY2023.
  • Ionis Pharmaceuticals' Cost of Revenue's 5-year high stood at $14.1 million during FY2022, with a 5-year trough of $9.1 million in FY2023.
  • For the 3-year period, Ionis Pharmaceuticals' Cost of Revenue averaged around $11.5 million, with its median value being $11.2 million (2024).
  • Its Cost of Revenue has fluctuated over the past 5 years, first surged by 172.51% in 2020, then slumped by 35.30% in 2023.
  • Yearly analysis of 5 years shows Ionis Pharmaceuticals' Cost of Revenue stood at $11.9 million in 2020, then declined by 9.25% to $10.8 million in 2021, then skyrocketed by 30.20% to $14.1 million in 2022, then slumped by 35.30% to $9.1 million in 2023, then climbed by 22.80% to $11.2 million in 2024.